XenoGesis, a Contract Research Organisation (CRO) located in Nottingham, UK, has invested in an Agilent AriaMx Real-time PCR system.
The equipment expands the firm's quantitative PCR capabilities and adds CYP induction assays to its portfolio of services.
The Agilent AriaMx Real-time PCR is a fully integrated quantitative PCR amplification, detection and data analysis system with a 96-well capacity.
The machine enables any gene expression assays to be carried out, which will expand XenoGesis’ range of assays beyond preclinical drug metabolism and pharmacokinetics (DMPK) to now include pharmacology services.
Senior Research Scientist Sally Stinson is leading the introduction of the techniques at the firm.
Stinson has many years of experience in carrying out qPCR experiments and offers in depth advice and carries out experimental work with regards to RNA/cDNA sample preparation from a range of cell types.
She can also perform a range of qPCR experiments looking at a variety of genes of interest.
XenoGesis Managing Director Richard Weaver said: 'This investment means we are now able to offer CYP induction assays and also work with clients to carry out any type of gene expression assays.
'We now have the facility to prepare RNA from a range of cell types and carry out cDNA preparation.'
